Mirati Therapeutics, Inc.
| Nasdaq: MRTX
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. It also focuses on its development programs on drugs intended to treat specific subsets of cancer patients with unmet needs. The company's pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, multi-targeted kinase inhibitors with distinct target profiles that are in development to treat patients with non-small cell lung cancer, or NSCLC, squamous cell carcinoma of the head and neck, or HNSCC, and other solid tumor. Mirati Therapeutics was founded on December 13, 1995 and is headquartered in San Diego, CA.